About Cullgen
Powering Protein Degradation for Tomorrow’s Medicines
Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class medicines for the treatment of diseases lacking effective therapeutic approaches. We utilize our proprietary technology platform, uSMITE™, featuring novel E3 ligands, to build the next generation of targeted protein degraders.
Our mission is to utilize our revolutionary and proprietary targeted protein degradation technology to create new drugs for the treatment of diseases that currently lack effective therapies.
Meet the Cullgen Team
Management Team
Ying Luo, Ph.D.
Chairman and President
Yue Xiong, Ph.D.
Chief Scientific Officer
Thomas Eastling
Chief Financial Officer
Seth Goldblum
Senior Vice President - Corporate Development
Xiaoran Han, Ph.D.
Vice President - Discovery Medicine
Leslie Robinson, Ph.D., J.D.
Vice President - Intellectual Property and Licensing
Ting Yang, Ph.D.
Vice President - CMC
Liang Zhao
Vice President - Corporate Controller
Mark Marino, M.D.
Senior Vice President-Clinical Development
Jing Liu, Ph.D.
Senior Vice President - Platform Chemistry
Michael Plewe, Ph.D.
Senior Vice President - Medicinal Chemistry
Jialiang Wang, Ph.D.
Executive Vice President - Operations
Joshua Bergmann, J.D.
Vice President - Legal and Corporate Secretary
Xiangyu Jin, M.D.
Vice President-Clinical Development
Board of Directors
Ying Luo, Ph.D.
Chairman
